Godavaridrugs

Secunderabad, India Founded: 1987 • Age: 39 yrs Listed
CMO services for APIs, intermediates, and fine chemicals are offered.

About Godavaridrugs

Godavaridrugs is a publicly listed company based in Secunderabad (India) founded in 1987. CMO services for APIs, intermediates, and fine chemicals are offered. The company has 92 employees. Its Indian entity Godavari Drugs Limited reported revenue of β‚Ή107 Cr. Godavaridrugs offers products and services including APIs, Drug Intermediaries, and Fine Chemicals. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Godavari Drugs Limited is in the business of Contract Manufacturing, Loan License Manufacturing, Manufacturing and Supply of API, drug intermediaries and fine chemicals. Reaction capabilities include Chiral chemistry including resolutions, asymmetric inductions, racemisation and asymmetric transformation, Vapor phase catalytic reactions at high temperature like oxidation, reduction, amoxidation, etc., High pressure liquid phase reactions like hydrogenation, oxidation, etc., Selenium chemistry including selenium oxidation reactions, Continuous distillative reactions in packed columns like esterifications, Oxidation using nitric acid, Piperazine based reactions along with recovery of piperazine, Chlorination, Grignard reaction, Friedel-kraft reaction

  • Headquarters Secunderabad, India
  • Employees 92
  • Stage Public
  • Sectors
    Healthcare
  • Website godavaridrugs.com
  • Social LinkedIn
  • Legal Name Godavari Drugs Limited
Key Metrics
  • Market Cap
    ₹126 Cr

    GODAVARI · BSE

  • Share Price
    ₹116.55

    +0.56% today

  • Revenue
    ₹106 Cr

    FY 2025-26 · -6.7% YoY

  • EBITDA
    ₹10.30 Cr

    Margin 9.7%

  • Net Profit
    ₹3.65 Cr

    FY 2025-26 · -15.7% YoY

  • P/E (TTM)
    35.0x

    P/B 1.7x

  • ROE
    6.9%

    ROCE 6.8%

  • Debt / Equity
    1.23

    Interest cover 50.6x

  • Employee Count
    92

Products & Services of Godavaridrugs

Godavaridrugs offers a comprehensive portfolio of products and services, including APIs, Drug Intermediaries, and Fine Chemicals.

APIs
Pharmaceutical Products

Active ingredients for pharmaceutical manufacturing and supply

Drug Intermediaries
Chemical Intermediates

Components used in drug production for global markets

Fine Chemicals
Specialty Chemicals

High-purity chemicals for life science applications

Board of directors of Godavari Drugs Limited (Godavaridrugs)

Godavari Drugs Limited is the primary company behind Godavaridrugs. The board of Godavari Drugs Limited currently have 6 directors; the longest-serving is Mukund Kakani, appointed in 1987. 10 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Mukund Kakani
DIN 00104646
Managing Director03 Dec 198738 yrs 11 moGodavari Drugs Limited
Ghanshyam Jaju
DIN 00104601
Director03 Dec 198738 yrs 11 moGodavari Drugs Limited
Mohit Jaju
DIN 03405414
Whole-time director10 May 201214 yrs 6 moGodavari Drugs Limited
Mahendra Uday Bhalerao
DIN 01876185
Director12 Nov 20224 yrsGodavari Drugs Limited
Dinesh Udpa
DIN 10503106
Director13 Feb 20242 yrs 9 moGodavari Drugs Limited
Shilpa Bung
DIN 08257931
Director29 May 20251 yr 5 moGodavari Drugs Limited

IPO & Listings of Godavaridrugs

Godavaridrugs is a publicly listed company on the BSE with ticker symbol GODAVARI in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date03 Jun 1995
  • Listed onBSE: 530317
  • Listed entityGodavari Drugs Limited
  • Exchange sectorHealth technology
  • ISININE362C01012
  • Share price₹131.55 (+0.04% on the day) · 2026-10-14
  • Market capitalisation₹133 Cr
  • Price to earnings28.0
  • EPS (diluted, trailing year)₹4.70
  • Volume (last session)5,219

Financials of Godavaridrugs

Exchange-reported figures of Godavari Drugs Limited, the listed company behind Godavaridrugs (BSE: GODAVARI).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹106 Cr
-6.7% YoY
EBITDA
₹10.30 Cr
-12.9% YoY
Profit After Tax
₹3.65 Cr
-15.7% YoY
Net Worth
₹75.80 Cr
+74.9% YoY
Total Assets
₹158 Cr
+46.0% YoY
Total Debt
₹81.94 Cr
+27.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10611315716016112395.70
Revenue growth-6.7%-27.7%-1.8%-0.9%+31.3%+28.2%-
EBITDA10.3011.8213.229.9211.309.836.03
EBITDA margin+9.7%+10.4%+8.4%+6.2%+7.0%+8.0%+6.3%
Profit before tax5.055.626.934.937.035.702.29
Net profit3.654.335.623.605.254.122.00
Net profit margin+3.5%+3.8%+3.6%+2.3%+3.3%+3.4%+2.1%
EPS (β‚Ή)4.045.827.375.036.975.482.66
Balance sheet
Total assets15810997.4969.9853.4355.6348.53
Net worth75.8043.3538.9733.4229.6324.3920.26
Total debt81.9464.3557.7735.8523.0730.4627.60
Cash & bank14.512.372.623.082.281.641.43
Net working capital71.6146.1153.0637.1927.8633.0726.01
Cash flow
Cash from operations0.7311.2018.4113.2211.231.336.24
Cash from investing(25.95)(19.51)(13.22)(8.64)(4.97)(1.25)(6.68)
Cash from financing37.358.07(5.65)(3.77)(5.62)0.130.34
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue28.2327.9633.1622.1826.6523.8125.5029.55
Revenue growth (YoY)+5.9%+17.4%+30.0%-24.9%+2.2%-26.1%--
Other income(0.12)0.150.250.270.640.010.110.10
Total expenses25.4325.4430.2219.7124.6520.9122.3926.97
EBITDA2.802.522.942.472.002.903.112.58
EBITDA margin+9.9%+9.0%+8.9%+11.1%+7.5%+12.2%+12.2%+8.7%
Depreciation0.610.590.610.610.600.600.670.64
Interest0.840.900.961.110.911.001.111.11
Profit before tax1.231.181.621.021.131.311.440.93
Tax0.270.070.330.260.120.260.550.15

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue28.2327.9633.1622.1826.6523.8125.5029.55
Revenue growth (YoY)+5.9%+17.4%+30.0%-24.9%+2.2%-26.1%--
Other income(0.12)0.150.250.270.640.010.110.10
Total expenses25.4325.4430.2219.7124.6520.9122.3926.97
EBITDA2.802.522.942.472.002.903.112.58
EBITDA margin+9.9%+9.0%+8.9%+11.1%+7.5%+12.2%+12.2%+8.7%
Depreciation0.610.590.610.610.600.600.670.64
Interest0.840.900.961.110.911.001.111.11
Profit before tax1.231.181.621.021.131.311.440.93
Tax0.270.070.330.260.120.260.550.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10611315716016112395.70
Revenue growth-6.7%-27.7%-1.8%-0.9%+31.3%+28.2%-
Other income1.160.980.620.880.280.410.33
Total expenses95.5110214315015011389.67
Employee cost5.705.035.134.844.963.943.45
EBITDA10.3011.8213.229.9211.309.836.03
EBITDA margin+9.7%+10.4%+8.4%+6.2%+7.0%+8.0%+6.3%
Depreciation2.432.451.991.941.701.221.16
Interest3.984.734.923.932.853.322.91
Profit before tax5.055.626.934.937.035.702.29
Tax0.971.251.381.151.781.580.29
Net profit3.654.335.623.605.254.122.00
Net profit margin+3.5%+3.8%+3.6%+2.3%+3.3%+3.4%+2.1%
EPS (β‚Ή)4.045.827.375.036.975.482.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.137.537.537.537.537.537.53
Reserves & surplus60.4235.8231.4425.8922.1016.8612.73
Shareholders' funds (net worth)75.8043.3538.9733.4229.6324.3920.26
Secured loans60.3649.8647.7710.615.107.2319.57
Unsecured loans21.5814.4910.0025.2417.9723.238.03
Total debt81.9464.3557.7735.8523.0730.4627.60
Total liabilities15810997.4969.9853.4355.6348.53
Assets
Gross block49.4949.4346.8846.2849.5744.0534.21
Net block30.3132.6126.6924.9126.2522.4313.81
Capital work in progress56.5429.9518.329.080.490.768.93
Investments0.000.000.000.000.000.000.00
Inventories46.0627.9420.6519.8610.0314.6517.75
Sundry debtors43.5842.3259.4257.9355.5845.1236.02
Cash & bank balances14.512.372.623.082.281.641.43
Loans & advances7.646.125.786.136.456.205.63
Total current assets11278.7588.4787.0074.3467.6160.83
Total current liabilities40.1832.6435.4149.8146.4834.5434.82
Net working capital71.6146.1153.0637.1927.8633.0726.01
Total assets15810997.4969.9853.4355.6348.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2.372.623.082.281.641.431.53
Net cash from operating activities0.7311.2018.4113.2211.231.336.24
Net cash from investing activities(25.95)(19.51)(13.22)(8.64)(4.97)(1.25)(6.68)
Net cash from financing activities37.358.07(5.65)(3.77)(5.62)0.130.34
Net change in cash12.14(0.25)(0.46)0.810.640.21(0.10)
Closing cash14.512.372.623.082.281.641.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-6.7%-27.7%-1.8%-0.9%+31.3%+28.2%-
EBITDA growth-12.9%-10.6%+33.3%-12.2%+15.0%+63.0%-
PBT growth-10.1%-18.9%+40.6%-29.9%+23.3%+148.9%+31.6%
Net income growth-15.7%-23.0%+56.1%-31.4%+27.4%+106.0%-
Revenue CAGR (3Y)-12.8%-11.1%+8.5%+18.6%+24.5%+23.9%+8.2%
EBITDA CAGR (3Y)+1.3%+1.5%+10.4%+18.1%+27.3%+34.5%+4.9%
Profitability & leverage
Net income margin+3.9%+3.9%+3.5%+2.4%+3.3%+3.4%+2.1%
Return on capital employed+6.8%+10.1%+14.1%+14.4%+18.1%+17.3%+11.6%
Return on net worth+6.9%+10.6%+15.3%+12.0%+19.4%+18.5%+10.2%
Debt / equity1.231.481.290.930.991.301.29
Long-term debt / equity0.490.380.290.380.490.570.50
Interest cover50.5750.4843.8149.2529.6938.5659.75
Efficiency & per share
Fixed asset turnover2.142.353.363.333.443.132.80
Inventory turnover2.864.677.7410.6813.067.575.59
Debtors turnover2.462.232.672.813.203.022.74
EPS (β‚Ή)4.045.827.375.036.975.482.66
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)69.6657.5651.7444.3839.3532.3826.90

Similar companies to Godavaridrugs

Godavaridrugs has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of Godavaridrugs

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Godavaridrugs

Websites that share an audience with Godavaridrugs (godavaridrugs.com).

Similar websites

Websites whose visitors overlap most with Godavaridrugs. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
google.com
100%
85.8B#1View details

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Godavaridrugs (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Godavaridrugs

Premium access

Complete news archive for Godavaridrugs

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Godavaridrugs

Godavaridrugs was founded in 1987.

Godavaridrugs is headquartered in Secunderabad, India. It is registered at Secunderabad, Telangana, India.

Godavaridrugs has 92 employees.

The primary company behind Godavaridrugs, Godavari Drugs Limited, reported revenue of β‚Ή107 Cr for FY 2026, down 7% year on year.

Godavari Drugs Limited is in the business of Contract Manufacturing, Loan License Manufacturing, Manufacturing and Supply of API, drug intermediaries and fine chemicals. Reaction capabilities include Chiral chemistry including resolutions, asymmetric inductions, racemisation and asymmetric transformation, Vapor phase catalytic reactions at high temperature like oxidation, reduction, amoxidation, etc., High pressure liquid phase reactions like hydrogenation, oxidation, etc., Selenium chemistry including selenium oxidation reactions, Continuous distillative reactions in packed columns like esterifications, Oxidation using nitric acid, Piperazine based reactions along with recovery of piperazine, Chlorination, Grignard reaction, Friedel-kraft reaction.

Godavaridrugs's top competitors include Laurus Labs, Symbiotec and SeQuent.

Godavaridrugs offers APIs, Drug Intermediaries, and Fine Chemicals.

Yes, Godavaridrugs is publicly traded on BSE under the ticker symbol GODAVARI.

Godavaridrugs operates through Godavari Drugs Limited.

The legal entities of Godavaridrugs currently have 7 directors, including Mohit Jaju, Mukund Kakani, Ghanshyam Jaju and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available